In partnership with
7 Stocks to Buy Before the Robots Take Over
The next AI trade may not be another chatbot.
It may be surgical robots, automated warehouses, smart factories, and machine vision systems already reshaping how companies operate.
MarketBeat’s new 7 Stocks to Buy Before the Robotics Revolution report reveals seven companies positioned across the automation boom, from robot builders and AI chip leaders to machine vision providers and factory automation giants.
This is where AI gets a body.
And as labor shortages, wage pressure, and supply chain stress push more companies toward automation, these stocks could move before the robotics story becomes impossible to ignore.
The report normally sells for $29.97, but it is free for a limited time.
An Improving Tape Still Needs Proof
Good afternoon. The short-term backdrop is getting healthier, but the common test across earnings and sector moves is whether participation can broaden and fundamentals can keep pace. Today’s market read The backdrop is improving, but stock selection still matters. 01. Market Direction: Improving. The short-term trend is getting healthier, but not everything is confirmed. 02. Market Participation: Fading. Fewer stocks are helping. 03. Strongest Sector: Technology. Investors are showing the most interest here right now.
Today’s market read
The backdrop is improving, but stock selection still matters.
01 Market Direction
Improving. The short-term trend is getting healthier, but not everything is confirmed.
02 Market Participation
Fading. Fewer stocks are helping.
03 Strongest Sector
Technology. Investors are showing the most interest here right now.
Paycom needs recurring demand to validate the rebound
Key points
Second-quarter revenue of $531.2 million and non-GAAP earnings per share both exceeded expectations.
Recurring and other revenue rose 11%, while adjusted operating cash earnings margin reached 44.2%.
Raised full-year guidance helps the recovery case, though total revenue growth of 7% to 8% remains the key benchmark.
A 54.4% one-month share-price gain leaves less room for softer guidance or decelerating recurring growth.
The market reacted forcefully to Paycom's second-quarter report, sending shares up 23.6% in the following session and extending an already sharp move. The response reflected more than an earnings beat. Investors saw evidence that sales momentum and operating discipline were improving at the same time.
Revenue rose 9.8% from a year earlier to $531.2 million, while recurring and other revenue increased 11%. The margin expansion to 44.2% in adjusted operating cash earnings matters because it shows the recovery is not relying on a single accounting line. Still, recurring demand has to remain the engine if the company is to sustain a stronger growth profile.
The chart has repaired quickly, with the shares above their 20-day and 50-day moving averages, yet they remain below the 52-week high. That leaves the next guidance update and recurring-revenue trend as the evidence that matters most. A rally of this size is more sensitive when the operating case has not fully cleared its own growth benchmark.
Materials strength needs a broader set of hands
Key points
Basic Materials gained 5.7% in the week through August 5, even as the sector fund saw an estimated $115.4 million redemption.
The fund is heavily weighted toward chemicals and represents large U.S.-listed materials companies rather than a direct commodity basket.
July manufacturing improved, but evidence across metals and forest products remains uneven.
Broader participation and steadier fund flows would make the rotation case more durable.
Basic Materials delivered a notable 5.7% weekly gain, but the move arrived alongside an estimated $115.4 million redemption from the sector fund. That mismatch is central to the read. Price action can show investors concentrating in selected exposures before broad fund flows confirm a more durable rotation.
Because the Materials Select Sector SPDR Fund tracks the S&,P 500 materials segment, its performance reflects an equity mix led by chemicals, miners, packaging, and construction-materials businesses. It is useful as a liquid sentiment gauge, but it does not settle the demand picture for every materials end market.
Improving manufacturing activity in July is constructive context, though metals and forest-products evidence remains mixed. The next confirmation would be more names participating in the advance and less tension between price gains and fund flows. Until then, the move is better understood as selective leadership than a settled sector-wide conclusion.
Medical devices are sharing a rally, not one earnings path
Key points
Butterfly Network reported $32.6 million in second-quarter revenue, above expectations, and raised its 2026 outlook.
A larger software and licensing mix lifted gross margin, though net losses and cash use remain material.
Haemonetics needs renewed revenue and earnings growth to complement its profitability.
Establishment Labs needs U.S. Motiva demand to support guidance and narrow its route to net profitability.
Medical-device shares have moved with unusual breadth, with the industry up 8.4% in one month and 24.1% in three months. But broad price participation does not make the earnings test uniform. Revenue quality, margin direction, and guidance separate the stories once expectations have risen.
Butterfly Network's second-quarter results supplied a clear example of mix improvement. Revenue reached $32.6 million, up 39% from a year earlier and above consensus, while gross margin rose to 71.4% as software and licensing contributed more to the business. The raised 2026 revenue outlook strengthens the operating narrative, even as losses and cash consumption remain material risks.
Haemonetics and Establishment Labs present different versions of the same scrutiny. The former needs growth to reaccelerate alongside an existing profitability base, while the latter needs U.S. Motiva demand to support its outlook and advance the path toward net profitability. In a strong group, those company-specific measures will likely matter more than the healthcare label.
The market snapshot and these reports point to the same discipline for the next stretch: watch whether leadership widens, whether flows follow price, and whether recurring revenue, margins, and guidance keep confirming the moves already visible on the tape.